The Dexcom G6, a fully new and improved Real-Time CGM System, is now approved by the FDA and will be making its way to the UK in future. The UK launch is planned for the 2nd half of 2018, subject to European Approval.
With no fingerstick calibrations, (although the option is still there if required) 10-day wear time, approval for ages 2 years and older, no paracetamol interference, simplified one button insertion, improvement on the G5 in terms of accuracy and convenience, this is a game changer.
The G6 will be one of the first products to emerge from Dexcom’s partnership with tech giant Verily formerly Google Life Sciences with continued and significant cost reduction.
Intended for adults and children from 2 years
No contraindication to paracetamol
Tiny insertion needle (25Ga)
Ten day sensor life
New one-button inserter
3 month life, no charging required
6 meter transmission range
Built-in Bluetooth Low Energy for direct transmission of CGM data to receiver and mobile device
System Receiver (Optional)
Alternative device to view data
Early data from the G6 has been very impressive. In one study, a 49-person trial testing the G6 sensor over 10 days of wear, 96 percent of blood glucose readings were within 20 mg/dl (1.1 mmol/l) of the true glucose value, making it the most accurate device Dexcom has released.